6MO Translational relevance of the combined treatment PARP inhibitors and AsiDNA in homologous recombination proficient tumors

Abstract

PARP inhibitors (PARPi) have shown significant benefits in cancer patients with deficient homologous recombination repair (HRD; induced by BRCA mutations for example). However, they show no or very limited efficacy in tumors with active or proficient homologous recombination repair (HRP). In the current study, we propose a novel therapeutic strategy, based on drug combination to achieve synthetic lethality independently of the tumor genetics.